UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Feb

    27

    On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

    Feb

    26

    Beyond the Diagnosis: Embracing the Humanity Behind Epilepsy Care

    Feb

    25

    Shining a Light on Resilience: Honoring Black History Month and Raising Awareness for Epilepsy

    Feb

    12

    Providing U.S. Policy Actions on Rare Disease

    Feb

    03

    Rare Disease Day 2025: Elevating the Lives of the Under-served and Under-represented

    Jan

    31

    Voices on Value: Supporting People Impacted by Rare Disease through an Effective Policy Landscape

    Jan

    16

    UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)

    Dec

    18

    Charting the Future: UCB’s 2024 Achievements are Fueling our 2025 Ambitions

    Dec

    06

    UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting

    Nov

    26

    UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting